Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

TriSalus Life Sciences (TLSI) Research & Development (2022 - 2026)

TriSalus Life Sciences has reported Research & Development over the past 5 years, most recently at $3.2 million for Q1 2026.

  • For Q1 2026, Research & Development rose 6.45% year-over-year to $3.2 million; the TTM value through Mar 2026 reached $14.9 million, changed 0.13%, while the annual FY2025 figure was $15.0 million, 15.39% down from the prior year.
  • Research & Development for Q1 2026 was $3.2 million at TriSalus Life Sciences, up from $2.6 million in the prior quarter.
  • Over five years, Research & Development peaked at $9.5 million in Q3 2023 and troughed at $2.6 million in Q4 2025.
  • A 5-year average of $5.1 million and a median of $4.8 million in 2022 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: skyrocketed 97.71% in 2023 and later crashed 61.91% in 2024.
  • Year by year, Research & Development stood at $6.3 million in 2022, then increased by 23.97% to $7.8 million in 2023, then crashed by 61.91% to $3.0 million in 2024, then decreased by 13.15% to $2.6 million in 2025, then increased by 25.14% to $3.2 million in 2026.
  • Business Quant data shows Research & Development for TLSI at $3.2 million in Q1 2026, $2.6 million in Q4 2025, and $5.2 million in Q3 2025.